Advancements and Challenges of Robotic Surgery for Hepatocellular Carcinoma

Robotic surgery has emerged as a significant technique in the treatment of Hepatocellular Carcinoma (HCC), offering potential advantages over traditional surgical methods. This minimally invasive approach aims to enhance surgical precision while reducing recovery times for patients. Recent studies indicate that robotic liver resection (RLR) has gained traction since its introduction in 2003, and its application in the field of oncology, particularly in liver surgeries, has expanded steadily.

HCC represents one of the leading causes of cancer-related mortality worldwide, with surgical resection being a primary curative strategy. According to the World Health Organization (WHO), liver cancer accounted for approximately 830,000 deaths in 2020, underscoring the urgent need for effective treatment modalities (WHO, 2021). Surgical options for HCC include open liver resection, laparoscopic liver resection, and RLR, each offering different benefits and drawbacks based on patient conditions (Kokudo et al., 2015).

A comprehensive review published in the Journal of Gastrointestinal Surgery highlights that robotic-assisted techniques yield shorter operative times and reduced blood loss compared to open procedures (Di Benedetto et al., 2022). For instance, RLR is associated with an average operative time of 181 minutes and an estimated blood loss of about 200 mL, compared to 400 mL for traditional open liver resections (Di Benedetto et al., 2022). However, the technology's adoption is tempered by limitations, including higher costs and the requirement for specialized training for surgeons.

Dr. Pei-Heng Li, a leading researcher in robotic surgery, points out the ergonomic advantages of robotic systems, which diminish surgeon fatigue and enhance visualization through magnified 3D imaging (Li et al., 2025). Despite these benefits, the learning curve for robotic surgery remains a challenge. A study published in the Annals of Surgery notes that while RLR offers better outcomes in specific contexts, the transition to robotic techniques requires careful training and practice to ensure patient safety (O’Connor et al., 2017).

Moreover, the current literature indicates that while RLR shows promise, there are significant gaps in long-term efficacy data. For instance, a meta-analysis of 2630 participants revealed that there are no significant differences in overall survival rates between RLR and laparoscopic liver resections at the three-year mark (Kamarajah et al., 2021). Additionally, the incidence of abdominal adhesions was notably higher in the RLR group, a factor that warrants further investigation (Di Benedetto et al., 2022).

The economic implications of robotic surgery cannot be overlooked. A recent systematic review found that robotic procedures, while offering various clinical advantages, are approximately $759 more expensive than conventional laparoscopic methods (Gavriilidis et al., 2020). This cost disparity raises questions about the broader accessibility of robotic surgery, particularly in healthcare systems with limited resources.

Looking ahead, advancements in robotic technology and surgical protocols may address current limitations. Innovations such as the Hinotori Surgical Robotics System and enhanced training methodologies promise to improve the safety and effectiveness of robotic liver resections (Nakamura et al., 2024). As more facilities adopt this technology, the landscape of surgical oncology may shift towards a preference for robotic-assisted procedures, contingent upon overcoming the financial and training barriers that currently exist.

In conclusion, robotic surgery represents a promising frontier in the treatment of HCC, potentially improving patient outcomes through enhanced precision and recovery. However, the path forward requires addressing the significant challenges of cost, training, and data collection to validate its efficacy fully. As the field evolves, ongoing research and clinical trials will be essential in shaping the future of robotic surgery in hepatocellular carcinoma treatment.

### References 1. Di Benedetto F, Magistri P, Di Sandro S, et al. Safety and Efficacy of Robotic vs Open Liver Resection for Hepatocellular Carcinoma. JAMA Surg. 2022;157(5):436-444. doi:10.1001/jamasurg.2022.5697 2. Gavriilidis P, Roberts KJ, Aldrighetti L, Sutcliffe RP. A comparison between robotic, laparoscopic and open hepatectomy: a systematic review and network meta-analysis. Eur J Surg Oncol. 2020;46(7):1214-1224. doi:10.1016/j.ejso.2020.03.227 3. Kokudo N, Hasegawa K, Akahane M, et al. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: the Japan Society of Hepatology 2013 update. Hepatol Res. 2015;45(2). doi:10.1111/hepr.12464 4. Kamarajah SK, Bundred J, Manas D, et al. Robotic versus conventional laparoscopic liver resections: a systematic review and meta-analysis. Scand J Surg. 2021;110(3):290-300. doi:10.1177/1457496920925637 5. Li PH, Ding ZW, Ye YQ. Application of Robotic Surgery in Hepatocellular Carcinoma. J Hepatocellular Carcinoma. 2025;12:1217-1220. doi:10.2147/JHC.S515987 6. Nakamura K, Koide T, Higashiguchi T, et al. The First Report on Liver Resection Using the Novel Japanese hinotori Surgical Robot System: first Case Series Report of 10 Cases. J Clin Med. 2024;13(24):7819. doi:10.3390/jcm13247819 7. O’Connor VV, Vuong B, St Y, DiFronzo A. Robotic Minor Hepatectomy Offers a Favorable Learning Curve and May Result in Superior Perioperative Outcomes Compared with Laparoscopic Approach. Am Surg. 2017;83(10):1085-1088. doi:10.1177/000313481708301014 8. WHO. Global Cancer Observatory: Cancer Today. 2021. Available from: https://gco.iarc.fr/today/home